ORBi: Detailled Reference

Article (Scientific journals)

Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?

Scheen, André

2021 • In Médecine des Maladies Métaboliques, 15 (1), p. 45 - 52

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/296823

DOI
10.1016/j.mmm.2020.11.001

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2021 MMM place des sulfamidés.pdf

Publisher postprint (789.75 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular safety; Guidelines; Hypoglycemia; Oral antidiabetic drug; Sulfonylureas; Internal Medicine; Endocrinology, Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicine

Abstract :

[en] Sulfonylureas (SU) for a long time occupied an essential role in the management of type 2 diabetes (T2D). However, the launch of new oral antidiabetic drugs (OAD), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has markedly changed the scene. Indeed, in contrast to SU, these new OAD (of course more expensive) offer the advantage of a very low risk of hypoglycemia and a beneficial impact on bodyweight. Furthermore, gliflozins have proven to exert a cardiovascular and renal protection in patients at high risk. This article is discussing the current place to be reserved to SU in the treatment of T2D, after a short recall about the risk of hypoglycemia and the cardiovascular safety. Contrasted positions still remain in the international literature which translate into different guidelines between countries, especially due to economic constraints. SU keep a place in the management of T2D, yet it becomes more and more limited. For sure, SU should be avoided among elderly frailty people and patients at high risk of hypoglycemia.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?

Publication date :

February 2021

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson s.r.l.

Volume :

15

Issue :

1

Pages :

45 - 52

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S195725572030081X?httpAccept=text/xml

Available on ORBi :

since 29 November 2022

Statistics

Number of views

35 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

4

Scopus citations^®
without self-citations

1

OpenCitations

0

Bibliography

Scheen, A.J., Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Med Mal Metab 9 (2015), 186–197.
Monnier, L., Auguste Loubatières : l'histoire des sulfamides hypoglycémiants. Med Mal Metab 8 (2014), 107–111.
Scheen, A.J., Les sulfamides hypoglycémiants, 50 ans après Loubatières. Rev Med Liege 51 (1996), 90–93.
Scheen, A.J., Lefebvre, P.J., Oral antidiabetic agents. A guide to selection. Drugs 55 (1998), 225–236.
Buysschaert, M., Les sulfamidés hypoglycémiants en 2018 : généralités et spécificités. Louv Med 137 (2018), 1–6.
Haute Autorité de santé (HAS), Agence nationale de sécurité du médicament et des produits de santé (Ansm), Stratégie médicamenteuse du contrôle glycémique du diabète de type 2. Recommandation de bonne pratique. 2013, Haute Autorité de santé, Saint-Denis La Plaine [http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf].
Scheen, A.J., À propos de l'expérience belge avec les inhibiteurs des SGLT2. Med Mal Metab 14 (2020), 320–330.
Scheen, A.J., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Scheen, A.J., Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Scheen, A.J., Traiter le patient diabétique de type 2 à risque : analyse critique des recommandations de l'European Society of Cardiology (ESC). Med Mal Metab 14 (2020), 472–481.
Halimi, S., Éditorial. Il y a 70 ans, la découverte française des sulfamides hypoglycémiants : quel est leur futur ?. Med Mal Metab 8 (2014), 5–6.
Grimaldi, A., Débat entre Bernard Charbonnel et Michel Marre : quelle place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 ?. Med Mal Metab 11 (2017), 537–538.
Monami, M., Dicembrini, I., Kundisova, L., et al. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 16 (2014), 833–840.
Zhang, Y., Hong, J., Chi, J., et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 30 (2014), 241–256.
Detournay, B., Halimi, S., Robert, J., et al. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vasc Health Risk Manag 11 (2015), 417–425.
Chen, Z., Li, G., Sodium-glucose co-transporter 2 inhibitors compared with sulfonylureas in patients with type 2 diabetes inadequately controlled on metformin: a meta-analysis of randomized controlled trials. Clin Drug Investig 39 (2019), 521–531.
Andersen, S.E., Christensen, M., Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. Br J Clin Pharmacol 82 (2016), 1291–1302.
Schernthaner, G., Grimaldi, A., Di Mario, U., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34 (2004), 535–542.
ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
Douros, A., Yin, H., Yu, O.H., et al. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care 40 (2017), 1506–1513.
Tanner, M., Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Ann Intern Med, 165, 2016, JC20.
Salvo, F., Moore, N., Arnaud, M., et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ, 353, 2016, i2231.
Douros, A., Dell'Aniello, S., Yu, O.H., et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ, 362, 2018, k2693.
Zoungas, S., Patel, A., Chalmers, J., et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363 (2010), 1410–1418.
Abdelmoneim, A.S., Eurich, D.T., Light, P.E., et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
Pop, L.M., Lingvay, I., The infamous, famous sulfonylureas and cardiovascular safety: much ado about nothing ?. Curr Diabetes Rep, 17, 2017, 124.
University Group Diabetes Program (UGDP) Research Group., A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Sections I and II. Diabetes 19:Suppl. 2 (1970), 747–830.
Scheen, A.J., Historique des études cardiovasculaires: de l'UGDP … aux dernières études. Med Mal Metab 11:Suppl. 1 (2017), 2S15–2S26.
University Group Diabetes Program, A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 25 (1976), 1129–1153.
UK Prospective Diabetes Study (UKPDS) Group., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853 [Erratum in: Lancet 1999; 354:602].
Scheen, A.J., Cardiovascular safety of DPP-4 inhibitors compared to sulphonylureas: Results of randomized controlled trials and observational studies. Diabetes Metab 44 (2018), 386–392.
Scheen, A.J., Sécurité cardiovasculaire des inhibiteurs de la DPP-4 comparée à celle des sulfamides hypoglycémiants. Rev Med Suisse 14 (2018), 1468–1472.
Bain, S., Druyts, E., Balijepalli, C., et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab 19 (2017), 329–335.
Farah, D., Leme, G.M., Eliaschewitz, F.G., Fonseca, M.C., A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. Diabetes Res Clin Pract 149 (2019), 47–63.
Azoulay, L., Suissa, S., Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40 (2017), 706–714.
Leiter, L.A., Latest evidence on sulfonylureas: what's new?. Diabetes Ther 11:Suppl. 1 (2020), 15–22.
Zoungas, S., ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. Diabetes Obes Metab 22:Suppl. 2 (2020), 5–11.
Vaccaro, O., Masulli, M., Nicolucci, A., et al. Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 5 (2017), 887–897 [Erratum in: Lancet Diabetes Endocrinol 2017;5:e7].
Scheen, A.J., Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 98 (2012), 175–186.
Rosenstock, J., Kahn, S.E., Johansen, O.E., et al. CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322 (2019), 1155–1166 [Erratum in: JAMA 2019; 322:2138].
Rosenstock, J., Perkovic, V., Johansen, O.E., et al. CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321 (2019), 69–79.
Genuth, S., Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!. Diabetes Care 38 (2015), 170–175.
Marre, M., Sulfamides hypoglycémiants : les diurétiques de la diabétologie. Med Mal Metab 11 (2017), 543–545.
Charbonnel, B., Quelle place reste-t-il pour les sulfamides hypoglycémiants dans la stratégie thérapeutique du diabète de type 2 ? Une place très réduite !. Med Mal Metab 11 (2017), 539–542.
Abrahamson, M.J., Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!. Diabetes Care 38 (2015), 166–169.
Khunti, K., Chatterjee, S., Gerstein, H.C., et al. Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes Endocrinol 6 (2018), 821–832.
Webb, D.R., Davies, M.J., Jarvis, J., et al. The right place for Sulphonylureas today. Diabetes Res Clin Pract, 157, 2019, 107836.
Mohan, V., Cooper, M.E., Matthews, D.R., Khunti, K., The standard of care in type 2 diabetes: re-evaluating the treatment paradigm. Diabetes Ther 10:Suppl. 1 (2019), 1–13.
Colagiuri, S., Matthews, D., Leiter, L.A., et al. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract 143 (2018), 1–14.
Khunti, K., Hassanein, M., Lee, M.K., et al. Role of gliclazide MR in the management of type 2 diabetes: report of a symposium on real-world evidence and new perspectives. Diabetes Ther 11:Suppl. 2 (2020), 33–48.
Wexler, D.J., Sulfonylureas and cardiovascular safety: the final verdict?. JAMA 322 (2019), 1147–1149.
Diop, S.N., Baldé, N., Sidibé, A.T., La bithérapie antidiabétique orale en pratique médicale courante en Afrique subsaharienne: résultats d'une étude observationnelle multicentrique sur six mois. Med Mal Metab 12 (2018), 306–312.
Kalra, S., Bahendeka, S., Sahay, R., et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab 22 (2018), 132–157.
Darmon, P., Bauduceau, B., Bordier, L., et al. Société Francophone du Diabète (SFD). Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2-2019. Med Mal Metab 13 (2019), 711–732.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Ivers, N.M., Jiang, M., Alloo, J., et al. Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes. Can Fam Physician 65 (2019), 14–24.
Buse, J.B., Wexler, D.J., Tsapas, A., et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63 (2020), 221–228 [Erratum in: Diabetologia 2020;63:1667].
Scheen, A.J., Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Med Mal Metab 12 (2018), 22–30.
Consoli, A., Czupryniak, L., Duarte, R., et al. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes Obes Metab, 2020, 10.1111/dom.14102 [Online ahead of print].
Diop, S.N., Djrolo, F., Traoré Sidibé, A., et al. Consensus pour la prise en charge de l'hyperglycémie dans le diabète de type 2 en Afrique subsaharienne. Rédigé par un groupe d'experts africains du diabète. Med Mal Metab 13 (2019), 210–216.

Similar publications